Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 8/20 | 0.52 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 7/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 7/20 | 0.42 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5570400 | 0.86 | FYN (0.53) | FYNPTPN11TGFBR1ACVR1MAP4K1 | |
| SCHEMBL5565503 | 0.83 | FYN (0.56) | FYNPTPN11TGFBR1ACVR1MAP4K1 | |
| SCHEMBL5571096 | 0.82 | CNR2 (0.56) | PTPN11CNR2 | |
| SCHEMBL5570224 | 0.79 | MAP4K4 (0.38) | FYNPTPN11 | |
| SCHEMBL11946789 | 0.77 | FYN (0.46) | FYN | |
| SCHEMBL985098 | 0.75 | FYN (0.52) | FYNPTPN11TGFBR1ACVR1LRRK2 | |
| SCHEMBL982354 | 0.74 | MAPK1 (0.39) | PTPN11 | |
| SCHEMBL4407498 | 0.74 | FYN (0.53) | FYNPTPN11TGFBR1ACVR1MAP4K1 | |
| SCHEMBL24681500 | 0.73 | FYN (0.65) | FYNTGFBR1ACVR1MAP4K1 | |
| SCHEMBL29914537 | 0.73 | FYN (0.65) | FYNTGFBR1ACVR1MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | claimed |
| US-8232406-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-31 | — | — | US | disclosed |
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| US-7872031-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | disclosed |
| EP-2004625-B1 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMA (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2007111904-A2 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | FYN 392/4885PTPN11 806/4885TGFBR1 2052/4885 |
| US-20070254868-A1 | C-MET protein kinase inhibitors | MET, PRKCH, ABL1 | FYN 392/4885PTPN11 806/4885TGFBR1 2052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.